Presentation

0 Comments

20 December 2016

Stent Thrombosis: Future Directions

New antiplatelet agents

Robert Storey

Previous | Next
Download

Summary

Robert Storey looks at the platelet activation mechanisms an the variable response to clopidogrel which might be responsible for stent thrombosis. He also talks about novel thienopyridine inhibitor – Prasurel and how it’s mechanism of action differs from clopidogrel and the TRITON -TIMI38 (To Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction) trial.  He also presents the data for PLATO trial that examined a novel agent Ticagrelor (non-thienopyridine, reversible, orally active, rapid onset of action and directly acting)vs Clopidogrel in patients presenting with NSTEMI and STEMI. Lastly he talks about Cangrelor.

Download

Summary

Robert Storey looks at the platelet activation mechanisms an the variable response to clopidogrel which might be responsible for stent thrombosis. He also talks about novel thienopyridine inhibitor – Prasurel and how it’s mechanism of action differs from clopidogrel and the TRITON -TIMI38 (To Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction) trial.  He also presents the data for PLATO trial that examined a novel agent Ticagrelor (non-thienopyridine, reversible, orally active, rapid onset of action and directly acting)vs Clopidogrel in patients presenting with NSTEMI and STEMI. Lastly he talks about Cangrelor.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In